WCN26-7552 Development of Potent and Selective NUAK1 Inhibitors that Attenuate TGF-β–Induced and UUO-Driven Renal Fibrosis via YAP Pathway Modulation

Read full text Summarise with VIRAT
Authors: Minji Seo, Jihye Yoon, Sungho Park, Minkyeong Jo, Hyomin Lee, Daehyun Kim, Young‐Shin Kwak
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Kidney fibrosis represents a self-perpetuating injury pathway that is activated in nearly all forms of chronic kidney disease (CKD) leading to end-stage renal disease (ESRD), yet no renal antifibrotic therapy has been developed to date. NUAK1, a member of the AMP-related kinase family, is upregulated in fibrotic tissues and correlated with progressive dysfunction in human transplant kidneys. Mechanistically, NUAK1 activates YAP/TAZ transcriptional activity by destabilizing a Hippo pathway kinase LATS1.

Fields of Study & Subjects

Hippo pathway signaling and YAP/TAZ Chronic Kidney Disease and Diabetes TGF-β signaling in diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105400–105400
Publication date
25 March 2026
Language
EN